Drs. Akhil Saji and Amir Lebastchi engage in an in-depth exploration of focal therapy for prostate cancer, covering its historical evolution, current techniques and energy modalities, the critical roles of MRI and biomarkers in patient selection and risk stratification, posttreatment follow-up protocols, management of recurrences, comparisons with alternative treatments such as radical prostatectomy, and a balanced advocacy for integrating focal therapy into clinical practice with careful patient selection.
Advertisement
Latest News
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
Conventional imaging may understage patients with HR nmHSPC compared to PSMA-PET imaging.
Dr. Lotan discusses risk stratification and outlines the next steps for integrating Cxbladder Triage into clinical practice.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
The indication for SG as a treatment for patients with pretreated aUC will be officially withdrawn by Gilead.
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Patients who achieved a complete response after six doses of UGN-101 were followed up for 12 months after initial CR.
Patients with BRCA mutations had a higher risk of death, while patients with PTEN/TP53/RB1 mutations did not.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Katy Beckermann, MD, PhDEditor | Medical Director of GU Clinical Research at Tennessee Oncology
Akhil Abraham Saji, MDEditor | Urologist at Swedish Health Services
David Ambinder, MDEditor | Urology Resident at New York Medical College/Westchester Medical Center
The Uromigos Live and Unplugged 2024
The Uromigos Live & Unplugged 2024 took place September 27-29 in Nashville, Tennessee.
This meeting was the third annual in-person event hosted by Thomas Powles, MD, and Brian Rini, MD, FASCO, in partnership with Mashup Media, featuring expert panels and audience discussion around the latest data in genitourinary oncology and vision for the future.
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
Expert Interviews
Drs. Saji and Lebastchi explore focal therapy, covering its historical evolution, techniques, and energy modalities.
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Dr. Brad McGregor shares exciting developments in the MIBC space and the challenges facing the field of GU oncology.
Dr. Kane shares insights into his career trajectory, highlighting moments that led him to specialize and leading in urology.
Dr. Li rationalizes the design and potential impact of the MoonRISe-1 study for intermediate-risk NMIBC.
Dr. Miles-Thomas shares the challenges of female urology and her vision for her tenure as AUA treasurer.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Episode 378: 2025 Preview of Important GU Data
Dr. Dorff reviews expectations for GU oncology updates in 2025.
# Posted on January 10, 2025
Conference Coverage
Live meeting highlights
Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.
Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.
Drs. Nizam and Packiam review the findings from a study on AI-powered biomarkers to aid NMIBC diagnosis and treatment.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Video Insights
Clinical discussions with experts in the field
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.